U.S. Markets close in 6 hrs 10 mins

Imprimis Pharmaceuticals, Inc. (IMMY)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.7000-0.0100 (-0.5848%)
As of 9:42AM EDT. Market open.
People also watch
IPWROCRXEVOKDPRXINNL
Full screen
Previous Close1.7100
Open1.7200
Bid1.7000 x 100
Ask1.7300 x 200
Day's Range1.7000 - 1.7200
52 Week Range1.4700 - 4.6900
Volume13,598
Avg. Volume178,023
Market Cap34.11M
Beta1.39
PE Ratio (TTM)-2.09
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Imprimis Pharmaceuticals, Inc. :IMMY-US: Earnings Analysis: Q2, 2017 By the Numbers : September 20, 2017
    Capital Cube21 hours ago

    Imprimis Pharmaceuticals, Inc. :IMMY-US: Earnings Analysis: Q2, 2017 By the Numbers : September 20, 2017

    Categories: Yahoo FinanceGet free summary analysis Imprimis Pharmaceuticals, Inc. reports financial results for the quarter ended June 30, 2017. We analyze the earnings along side the following peers of Imprimis Pharmaceuticals, Inc. – Akorn, Inc., Antares Pharma, Inc., Retractable Technologies, Inc., Delcath Systems, Inc., ICU Medical, Inc. and Tandem Diabetes Care, Inc. (AKRX-US, ATRS-US, RVP-US, DCTH-US, ICUI-US ... Read more (Read more...)

  • Associated Presslast month

    Imprimis posts 2Q profit

    On a per-share basis, the San Diego-based company said it had net income of 6 cents. The pharmaceutical and drug compounding company posted revenue of $6.9 million in the period. In the final minutes of ...

  • Forbes2 months ago

    FDA Links Naturopathic Turmeric Death To Contaminated Product

    A curcumin emulsion for injection made by compounding pharmacy ImprimisRx contained a dangerous impurity. The company formulates a variety of questionable products for intravenous use and pays a popular naturopathic doctor as a consultant.